We are live on ! Find out more
MAIA icon

MAIA Biotechnology
MAIA

14 hedge funds and large institutions have $700K invested in MAIA Biotechnology in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

17% more funds holding

Funds holding: 12 → 14 (+2)

0.04% less ownership

Funds ownership: 2.36% → 2.33% (-0.04%)

1% less capital invested

Capital invested by funds: $709K → $700K (-$9.45K)

Holders
14
Holders Change
+2
Holders Change %
+16.67%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
+$49.5K
2
FIA
FNY Investment Advisers
New York
+$34.7K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$20.9K
4
BlackRock
BlackRock
New York
+$11.8K
5
Morgan Stanley
Morgan Stanley
New York
+$10.1K

Top Sellers

Rank Fund Capital Flow
1
LCM
Lynwood Capital Management
Ontario, Canada
-$77K
2
Citadel Advisors
Citadel Advisors
Florida
-$51.5K
3
Renaissance Technologies
Renaissance Technologies
New York
-$24K

MAIA Hedge Fund Activity: Q3 2023 in Review

14 of the 6,311 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q3 2023, worth a combined $700K — down 1.3% from $709K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new MAIA positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 0 trimmed.

The largest buyer was Bridgeway Capital Management, adding an estimated $49.5K. The largest seller was Lynwood Capital Management, exiting entirely with an estimated $77K sold.

  • 14 institutional investors held MAIA Biotechnology (MAIA) as of Q3 2023, up from 12 in Q2 2023.
  • Funds reported $700K of MAIA Biotechnology stock for Q3 2023, down 1.3% quarter-over-quarter.
  • 5 funds opened new MAIA Biotechnology positions in Q3 2023 and 3 closed out, a net change of +2 holders.
  • The largest MAIA Biotechnology buyer in Q3 2023 was Bridgeway Capital Management, an estimated $49.5K added.
  • The largest MAIA Biotechnology seller in Q3 2023 was Lynwood Capital Management, an estimated $77K sold.

Based on aggregated 13F filings for Q3 2023.